Low Expression of DDX60 Gene Might Associate with the Radiosensitivity for Patients with Breast Cancer.

Dongrun Xin,Lu Sun,Hualong Qin,Jincheng Gu,Jingfang Liu,Zaixiang Tang,Qingliang Tai,Jiawei Jin,Yujie Ji,Jianping Cao,Ye Tian

doi:10.1155/2020/8309492

Abstract

DEXD/H box helicase 60 (DDX60) is a new type of DEAD-box RNA helicase, which is induced to express after virus infection. It might involve in antiviral immunity by promoting RIG-I-like receptor-mediated signal transduction. In addition, previous studies had shown that the expression of DDX60 is related to cancer, but there was still a lack of relevant research in breast cancer. In this study, we used the information of patients with breast cancer in the TCGA database for statistical analysis and found that the breast cancer patients with low expression of DDX60 exhibited radiosensitivity. Comparing the radiotherapy groups with the nonradiotherapy groups, for patients with low expression of DDX60, the adjusted hazard ratio (HR) values for radiotherapy were 0.244 (0.064–0.921) and 0.199 (0.062–0.646) in the training and validation datasets, with the p values 0.040 and 0.007, respectively. However, for patients with high expression of DDX60, the adjusted hazard ratio (HR) values were 3.582 (0.627–20.467) and 2.421 (0.460–12.773), with the p values 0.054 and 0.297, respectively. These results suggested that the expression of DDX60 might strongly associate with individualized radiosensitivity in patients with breast cancer.

Highlights

Breast cancer is one of the most common cancers in the world, accounting for a large proportion of cancer deaths in the world. e GLOBOCAN2018 showed that more than 2 million people were newly diagnosed with breast cancer in 2018, and nearly 627000 people died of breast cancer [1]
Radiosensitivity was defined as the improved survival benefits of patients receiving radiotherapy. en, the genes that could predict individual radiosensitivity were defined as radiosensitive genes. eir coding products could be used as potential biomarkers for radiosensitivity prediction
Using the Cox proportional hazard model, we analyzed the relationship between 13 clinical factors and the overall survival of breast cancer patients, and listed the hazard ratio (HR) and p values

Summary

Introduction

Breast cancer is one of the most common cancers in the world, accounting for a large proportion of cancer deaths in the world. e GLOBOCAN2018 showed that more than 2 million people were newly diagnosed with breast cancer in 2018, and nearly 627000 people died of breast cancer [1]. For women aged 30 to 59, breast cancer was the most common diagnosed cancer. It was the leading cause of cancer death for women who are younger than 45 years old [2]. With the wide application of radiotherapy in clinical practice, researchers have paid more attention on how to make better use of radiotherapy to improve the life quality of breast cancer patients. There have been many studies on radiotherapy for breast cancer, and researchers have proposed some options about its improvement and regimens [3,4,5]. Researchers did not have a unified view on the improvement of radiotherapy for breast cancer. Researchers did not have a unified view on the improvement of radiotherapy for breast cancer. e sensitivity of different individuals to radiotherapy was different. erefore, it is hoped that patients with radiosensitivity can be predicted by testing potential biomarkers. en, oncologists

Methods

Results

Conclusion